Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." What causes SLE? Experts ...

The median follow-up was 15 months (range, 4 to 29). The mean (±SD) duration of B-cell aplasia was 112±47 days. All the patients with SLE had DORIS remission, all the patients with idiopathic ...

In line with this, EULAR has updated its recommendations for managing SLE. The updated recommendations were developed by a multidisciplinary task force of patient research partners and healthcare ...

However, they stress that non-pharmacological options should not replace drug therapy when it is required, and refer readers to the full management recommendations for SLE and SSc.

SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus (SLE) with extrarenal involvement. The FDA’s ...

Systemic lupus erythematosus (SLE) is the most common type of lupus, a chronic autoimmune disease. Symptoms include fatigue, joint pain, and rashes across your nose and cheeks. While there’s no ...